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Sales of CS Between Registrants
A pharmacy is authorized to transfer (sell) a controlled 
substance (CS) to another registrant, such as another pharmacy 
or a practitioner, but only in accordance with state and federal 
rules and regulations. A pharmacy wishing to sell or transfer 
a CS to another registrant must ensure that the individual or 
pharmacy is legally authorized to handle that CS. To ensure 
that the correct legal authority is in place, the pharmacy should 
verify the current Controlled Substances Act registration and 
professional licensure of  the pharmacy or practitioner seek-
ing the substance. Once verified, the pharmacy must create a 
distribution record of  the substance being transferred or sold, 
in compliance with Iowa Pharmacy Board Rule 657.10.16(1). 
This record is not unlike an invoice provided by a wholesale 
distributor. One copy needs to be provided to the purchaser 
and one copy is to be retained in the pharmacy’s records. The 
pharmacy must not process the transfer of  CS through its phar-
macy software system as a prescription record, as these are 
not prescriptions. Drug Enforcement Administration (DEA) 
has noted recently that it is still seeing pharmacy prescription 
monitoring program (PMP) reports with such distributions 
listed. Sales and transfers must be handled as a distribution, 
including a record that is maintained with other receipt and 
distribution records.
Can a pharmacy request a Schedule II prescription from 
a prescriber? Yes. A pharmacy can relay to a prescriber a 
patient’s request for a Schedule II prescription. The pharmacy 
may not, however, provide a pre-populated prescription for the 
prescriber to simply sign. DEA reserves the task of  preparing 
a prescription for the prescriber’s signature to an agent of the 
prescriber, which a pharmacist or pharmacy is not. The phar-
macy may provide the prescriber with information relating to 
the prescription being requested by the patient, but it cannot 
be in such a form that is essentially preparing the prescription 
for the prescriber’s signature.
TPV Programs Update
In the December 2018 Newsletter, information was pro-
vided following the amendment to Iowa Administrative Code 
(IAC) during the 2018 legislative session relating to techni-
cian product verification (TPV) programs. The IAC changes 
followed a multi-year demonstration pilot study conducted 
by the Iowa Pharmacy Association and Drake University 
College of  Pharmacy and Health Sciences to study the safety 
and impact of TPV programs in the community setting to 
increase pharmacist availability for the provision of  clinical 
pharmaceutical services. The study’s results showed that pa-
tient safety was not impacted; therefore, the Iowa Legislature 
authorized the practice of  TPV through an amendment in the 
IAC. As authorized, the Board developed a proposed revision 
to IAC Chapter 40, Tech-Check-Tech Programs, and sent the 
proposed revised chapter to all pharmacists and technicians in 
Iowa to solicit feedback before officially submitting a Notice of 
Intended Action. The Board received approximately 30 com-
ments to the proposed revision. From those comments, several 
changes were made to the proposed revision of  Chapter 40. 
The updated, revised chapter was approved by the Board for 
submission as a Notice of  Intended Action to formally start 
the rulemaking process. The rulemaking is available for public 
comment until March 5, 2019. The Board welcomes all inter-
ested parties to comment on the proposed rulemaking. You 
may submit your comments online at https://rules.iowa.gov.
Statewide Protocols Update
In the December Newsletter, information was provided on 
the Iowa Code provision authorizing the Board to develop 
statewide protocols, in collaboration with the Iowa Department 
of  Public Health, for pharmacists to order and administer med-
ications relating to naloxone, nicotine replacement tobacco 
cessation therapy, and immunizations. The Board has adopted 
rulemaking to establish the minimum standards for pharmacists 
who wish to participate in any or all of  the statewide protocols 
upon their release. The rulemaking will become effective on 
March 6, 2019, and includes such parameters as pharmacist 
training and education, as well as required notification to the 
patient’s primary care provider following the provision of a 
medication or immunization. The rules are available on the 
Board’s website. The Board is actively working on developing 
and finalizing the statewide protocols for these three practice 
areas. Check the Board’s website for updates.
trolled Substances Act. FDA approved Epidiolex for the 
treatment of seizures associated with two rare and severe 
forms of epilepsy, Lennox-Gastaut syndrome and Dravet 
syndrome, in patients two years of age and older on June 




ASHP Guidelines Provide 
Recommendations for Preventing 
Patient Harm From Medication Errors
New guidelines from the American Society of Health-
System Pharmacists (ASHP) describe opportunities for 
pharmacists on interprofessional teams to prevent errors 
across the continuum of care in hospitals and health sys-
tems. The “ASHP Guidelines on Preventing Medication 
Errors in Hospitals” are intended to apply to the acute 
care setting because of the special collaborative processes 
established in this setting. However, these guidelines may 
be applicable to practice settings outside of the acute care 
setting, especially in health systems.
Further, the ASHP press release notes that the guide-
lines address numerous areas in the medication-use 
process where errors may occur, including: patient ad-
mission; selection and procurement; storage; ordering, 
transcribing, and reviewing; preparation; dispensing; 
administration; monitoring; evaluation; and patient 
discharge. Published in the October 1, 2018 issue of the 
American Journal of Health-System Pharmacy, the guide-
lines are available at www.ajhp.org/content/75/19/1493. 
ASHP’s October 2, 2018 press release can be found in 
the News section at www.ashp.org.
FDA’s Final Guidance Documents 
Address Compounding and 
Repackaging of Radiopharmaceuticals
On September 26, 2018, FDA published the final 
guidance titled Compounding and Repackaging of Radio-
pharmaceuticals by Outsourcing Facilities. In this final 
guidance for industry, FDA sets forth its policy regarding 
compounding and repackaging of radiopharmaceuticals 
for human use by entities that are registered with FDA as 
outsourcing facilities. This guidance describes how FDA 
generally intends to apply section 503B of the Federal 
Food, Drug, and Cosmetic Act (FD&C Act) to radio-
pharmaceuticals compounded by outsourcing facilities. 
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Final Guidance Documents Address 
FDA Policies Related to DSCSA
To help ensure that prescription drug products are 
identified and traced properly as they move through the 
supply chain in compliance with federal law, Food and 
Drug Administration (FDA) issued two final guidance 
documents related to the Drug Supply Chain Security Act 
(DSCSA). Released on September 19, 2018, the follow-
ing final guidance documents will help ensure there are 
no disruptions in the supply chain as manufacturers and 
repackagers include a product identifier on the package 
or case.
♦ Product Identifier Requirements Under the Drug
Supply Chain Security Act – Compliance Policy
addresses industry-wide readiness for implementa-
tion of the new requirements aimed at enhancing
the security of the drug supply chain. As the agency
continues to work with stakeholders to ensure proper
implementation of the law, this guidance document
specifies FDA’s one-year delay in enforcing the
manufacturers’ requirement to include a product
identifier on the package or case of products to
November 27, 2018.
♦ Grandfathering Policy for Packages and Homog-
enous Cases of Product Without a Product Identifier
outlines the circumstances in which packages and
cases of product that were in the supply chain before
the November 2018 product identifier requirement
are considered grandfathered. The grandfathering
policy describes the circumstances under which
products already in the supply chain can remain in
distribution without being relabeled with a product
identifier.
The final guidance documents can be found at www 
.fda.gov/newsevents/newsroom/fdainbrief/ucm621095 
.htm.
First FDA-Approved Drug Containing 
Extract From Cannabis Plant to Be 
Placed in Schedule V
On September 27, 2018, the United States Department 
of Justice and Drug Enforcement Administration (DEA) 
announced that Epidiolex® – which contains cannabidiol, 
a chemical constituent of the cannabis plant, and is the 
first FDA-approved drug to contain a purified extract 
from the plant – is being placed in Schedule V of  the Con-
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In addition, this guidance describes the conditions under 
which FDA generally does not intend to take action for 
violations of certain provisions of the FD&C Act when 
an outsourcing facility repackages radiopharmaceuticals, 
according to the Federal Register notice at www.gpo.gov/
fdsys/pkg/FR-2018-09-26/pdf/2018-20901.pdf. 
At the same time, FDA published the final guidance 
titled Compounding and Repackaging of Radiophar-
maceuticals by State-Licensed Nuclear Pharmacies, 
Federal Facilities, and Certain Other Entities. This 
guidance sets forth FDA’s policy regarding compound-
ing and repackaging of radiopharmaceuticals for human 
use by state-licensed nuclear pharmacies, federal facili-
ties, and other entities that hold a radioactive materials 
license for medical use issued by the Nuclear Regulatory 
Commission or by an Agreement State. Because such 
radiopharmaceuticals are not eligible for exemptions 
from provisions of the FD&C Act related to the produc-
tion of drugs, FDA is issuing this guidance to describe 
the conditions under which it generally does not intend 
to take action for violations of certain provisions of the 
FD&C Act when these entities compound or repackage 
radiopharmaceuticals. More details are available in the 
Federal Register notice at www.gpo.gov/fdsys/pkg/FR-
2018-09-26/pdf/2018-20902.pdf.
Pharmacy Toolkit Encourages 
Conversations With Patients About 
Prescription Opioids
In collaboration with its pharmacy partners and several 
state pharmacy associations, Allied Against Opioid 
Abuse (AAOA) developed a Pharmacy Toolkit to help 
pharmacists engage and educate patients about the safe 
use, storage, and disposal of pain medicines. The AAOA 
Pharmacy Toolkit includes resources to help pharmacists 
raise awareness among patients about their rights, risks, 
and responsibilities associated with prescription opioids. 
These resources include: a pharmacy display, patient 
handout, patient engagement guide, tips for talking with 
patients and caregivers, prescriber engagement guide, 
safe storage and disposal training, and social graphics. 
To learn more about the Pharmacy Toolkit and to 
obtain these resources, visit AAOA’s website at https://
againstopioidabuse.org.
Biosimilars Added to FIP’s Policy on 
Pharmacists’ Right to Substitute a 
Medication
To account for the emergence of biological medicines 
and their biosimilars onto the medical landscape, the 
International Pharmaceutical Federation (FIP) has added 
biosimilars to its policy on pharmacists’ right to substi-
tute one medicine for another. The revised Statement of 
Policy titled “Pharmacist’s authority in pharmaceutical 
product selection: therapeutic interchange and substitu-
tion” includes the core principles of  the original statement 
and the following: 
♦ generic substitution is recommended as part of the
pharmacist’s dispensing role;
♦ pharmacists should be provided with bioavailability
data by regulatory authorities and manufacturers;
and
♦ a medicine should only be substituted with a product
containing a different active ingredient in agreement
with the prescriber.
According to FIP’s October 2, 2018 press release, the 
use of generic names is still encouraged, but the revised 
statement gives focus to the use of international nonpro-
prietary names. The full Statement of Policy and press 
release are available at www.fip.org in their respective 
sections.
FDA Offers CE Course on Reducing 
Hypoglycemic Events in Patients With 
Type 2 Diabetes
FDA is offering a free, one-hour continuing educa-
tion (CE) course for health care providers (physicians, 
pharmacists, nurses, and others) about the reduction of 
hypoglycemic events in patients with Type 2 diabetes. 
The course, Leveraging Health Literacy and Patient 
Preferences to Reduce Hypoglycemic Events in Patients 
with Type 2 Diabetes, will describe the prevalence of 
hypoglycemic events and identify risk factors leading 
to an event. Available for credit through October 31, 
2020, this course will introduce methods of assessing 
health literacy and numeracy of patients and caregivers; 
review effective ways to incorporate patient prefer-
ences into care plans; and list action steps to reduce 
the likelihood of a hypoglycemic event for high-risk 
patients. To participate in this CE course, visit http://
fdapasediabetes.e-paga.com. 
The FDA Center for Drug Evaluation and Research 
(CDER) is accredited by the Accreditation Council for 
Pharmacy Education (ACPE) as a provider of continu-
ing pharmacy education (CPE). This program meets 
the criteria for one contact hour (0.1 CEU) of CPE 
credit. The ACPE Universal Activity Number for this 
knowledge-based activity is 0453-9999-17-449-H01-P. 
Further, FDA’s CDERLearn in the CDER offers a variety 
of learning opportunities, which can be found at www.fda 
.gov/Training/ForHealthProfessionals/ucm545645.htm.
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Chapter 37: Iowa PMP Update
Information was also provided in the December Newslet-
ter on the myriad elements of  House File 2377, known as 
the Opioid Bill, and the possible changes to rules that are 
expected.  The bill passed during the 2018 legislative session. 
The Board approved a proposed revised IAC 657 – Chapter 
37 to be submitted for Notice of  Intended Action to start the 
rulemaking process. The public comment period was open 
until January 22, after which the rules committee and the 
Board considers comments and makes changes to the rule-
making as deemed appropriate. The Board will likely consider 
the proposed rules for final adoption at its March meeting. As 
always, all published rulemaking documents can be found at 
https://rules.iowa.gov.
Electronic Prescribing Mandate – 
January 1, 2020
In 2018, the Iowa Legislature passed legislation that will 
require all prescriptions, including CS, to be electronically 
prescribed by prescribers and electronically received by phar-
macies beginning January 1, 2020.
According to Surescripts data from October 2018, Iowa 
prescribers’ e-prescribing activity is still well below national 
averages. Of  Iowa prescribers, 66.5% (versus 73.6% nation-
ally) are submitting electronic prescriptions to pharmacies. 
A total of 63% of  Iowa’s prescribers have certified, audit-
approved software that is capable of  transmitting electronic 
prescriptions for controlled substances (EPCS). Yet, only 
15.3% of  Iowa’s prescribers have enabled this feature within 
their e-prescribing software (versus 30.4% nationally).
Conversely, Iowa’s pharmacies are on par with the national 
average for the ability to receive electronic prescriptions 
(98.1% versus 98.4%, respectively) while the rate of EPCS-
enabled pharmacies in Iowa hedges out the national averages 
by nearly 2% (96.7% versus 94.8%, respectively).
The legislation requiring e-prescribing permitted several 
exceptions to the e-prescribing mandate. Exclusions from the 
mandate include prescriptions that:
1. Are for a patient residing in a nursing home, long-term
care facility, correctional facility, or jail.
2. Are authorized by a licensed veterinarian.
3. Are dispensed by a United States Department of  Vet-
erans Affairs pharmacy.
4. Require information that makes electronic submission
impractical, such as complicated or lengthy directions
for use or attachments.
5. Are for a compounded preparation containing two or
more components.
6. Are issued in response to a public health emergency
in a situation where a non-patient-specific prescription
would be permitted.
7. Are issued pursuant to an established and valid col-
laborative practice agreement, standing order, or drug
research protocol.
8. Are issued during a temporary technical or electronic
failure at the practitioner’s or pharmacy’s location,
provided that a prescription issued pursuant to this
exception shall indicate on the prescription that the
practitioner or pharmacy is experiencing a temporary
technical or electronic failure.
9. Are issued in an emergency situation pursuant to fed-
eral law and regulation rules of  the Board.
Additionally, a practitioner, medical group, or pharmacy 
that is unable to timely comply with the electronic prescribing 
requirements may petition the Board for an exemption based 
on economic hardship; technical limitations that the practi-
tioner, medical group, or pharmacy cannot control; or other 
exceptional circumstances. The Board may grant exception 
requests for a period of time that may not exceed one year, 
which may be renewable with Board approval. The Board is 
in the process of creating the necessary forms and rules to 
establish the exception-petition framework.
After the mandate becomes effective on January 1, 2020, a 
pharmacist who receives a written, oral, or faxed prescription 
that is otherwise legitimate will not be required to verify that 
the prescription is subject to an exception listed above and 
may dispense the prescription. However, a pharmacist must 
exercise professional judgment in identifying and reporting 
suspected violations of the e-prescribing mandate to either 
the Board or the appropriate professional licensing board of 
the practitioner.
A prescriber who violates this mandate is subject to an 
administrative penalty of  $250 per violation, up to a maxi-
mum of  $5,000 per calendar year. The administrative penalty 
assessed by the prescriber’s primary licensing board will not 
be considered a disciplinary action or reported as discipline. 
A practitioner may appeal the assessment of  the administra-
tive penalty, which will initiate a contested case proceeding. 
The administrative penalties collected will be deposited into 
the drug information program fund to further support and 
enhance the state’s PMP.
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